Evaluating Nafamostat Mesylate for Dialysis Patients at High Risk of Bleeding

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study compares the safety and efficacy of Nafamostat Mesylate to low molecular weight heparin in patients undergoing hemodialysis who are at high risk for bleeding complications. The study aims to determine whether Nafamostat can provide a safer alternative for anticoagulation in this vulnerable population. Participants will be monitored for bleeding events and other complications during the treatment period. The study focuses on patients with specific bleeding risks, including those with low platelet counts and recent major surgeries.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month

Exclusion Criteria:

* cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)

Where it's running

• Yonsei Unviersity Wonju College of Medicin
  Wŏnju, Kangwondo, South Korea Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Italian Registry of Pediatric Dialysis: collecting data from kids on kidney replacement therapy

  This registry in Italy tests how collecting epidemiological, clinical, and treatment data from children on dialysis or pre-emptive kidney transplants can help centers share protocols and improve care.

  Recruiting at 12 sites Istituto Giannina Gaslini · Ancona and 11 other locations · NCT07918066

• 3D Ultrasound Support for Hemodialysis Cannulation

  This study tests whether the EchoMap device can help safely cannulate an arm fistula during hemodialysis for adults.

  Recruiting at 3 sites Sonavex, Inc. · Hartford, Connecticut and 2 other locations · NCT07891741

• Antiplatelet-Only versus Antiplatelet plus Low-Dose Rivaroxaban after Heart Events

  In adults 65 or older with prior heart events and certain arterial diseases, this study tests whether continuing clopidogrel alone is no worse than adding low-dose rivaroxaban to aspirin-based therapy.

  Recruiting Phase 4 Seoul National University Bundang Hospital · Seongnam-si, Gyeonggi-do · NCT07796217

• Laser acupuncture for fatigue in adults on hemodialysis

  This trial tests whether low-level laser acupuncture can reduce fatigue and improve quality of life for adults with end-stage kidney disease who are on regular hemodialysis, compared with a sham treatment.

  Recruiting Taipei City Hospital · Taipei · NCT07538310

• Multi-omics search for clotting and bleeding markers in coronary heart disease

  This project will test whether combining proteins, metabolites, genes, sugar tags, and heart images can better predict clotting and major bleeding in people with coronary heart disease on dual antiplatelet therapy.

  Recruiting at 3 sites Chinese Academy of Medical Sciences, Fuwai Hospital · Zhengzhou, Henan and 2 other locations · NCT07523880

• Apixaban vs Warfarin in HeartMate 3 LVAD Patients

  This study tests whether apixaban can replace warfarin to prevent clots and bleeding problems in adults with an implanted HeartMate 3 LVAD for at least 3 months.

  Recruiting Phase 3 Columbia University · New York, New York · NCT07471139

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.